Results of Covaxin trials on children likely to be out by Sept: AIIMS chief

Trials for Bharat Biotechs Covid19 vaccine Covaxin on children are underway and results are expected to be released by September All India Institute of Medical Sciences AIIMS director Randeep Guleria informedVaccines for children should come out now because trials in India are already underway for vaccines which are available in India Bharat Biotechs trial is in the final phase and by September we will have the data Guleria told ANIHe added In the coming weeks or by September vaccines should be available for children We should then start schools in a graded manner as we have been doing for 1845 years age and that also will give more protection to kids and more confidence to the public that children are safeThe trial is being conducted in three phases by segregating children into categories according to their age The first trial was started in the age group of 12 to 18 years followed by the age group of 6 to 12 Trials for children between the ages of and 26 years are currently undergoing trialsHe further said that vaccine manufacturer Zydus Cadila which recently requested emergency use authorisation for its Covid19 vaccine ZyCovD has also included the data for children for their vaccineZydus Cadila vaccine has also included children and their data is already there They have already applied for the emergency use authorization he saidZydus Cadila has concluded its trial for children between the age group of 12 to 18 The Ahmedabadbased pharmaceutical firm had on July 1 requested emergency use approval for its threedose Covid19 shot the worlds first Plasmid DNA vaccineIt will however be a few more days before the countrys drug regulator Drugs Controller General of India DCGI gives it emergency use authorisation as per sourcesThe Government of India has been holding discussions with Covid19 vaccine manufacturers Moderna and Pfizer for procuring their vaccine However there has been a delay over the sameThere could be multiple reasons of delay I think two or three things need to be kept in mind One is collaboration and the understanding with the government on the doses They should have enough doses to give because we must understand that these companies have prebooked the order from many countries he saidThey cannot spare doses for other countries unless they fulfil obligations to countries that have already placed orders the AIIMS director addedIndia has been in discussions with the two firms on several issues including indemnity waiverEarlier Dr V K Paul Member Health NITI Aayog had said We are holding discussions It is a process of negotiation and dialogues We are trying to get a solution on contractual and commitments issues This process is ongoingThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever